Corium International

Corium is a commercial-stage biopharmaceutical company leading the development of new transdermal healthcare products that provide clinicians with important treatment options for patients and their families. We are innovators focused on developing, manufacturing and commercializing specialty CNS pharmaceuticals for our own pipeline. Our lead product, CorplexTM Donepezil, is a once-weekly transdermal patch containing the active ingredient in Aricept® for the treatment of patients with mild, moderate and severe Alzheimer’s disease. Collaborating with some of the world’s largest pharmaceutical and consumer product companies, we have a track record of taking products from concept through development to commercial manufacturing. Corium’s transdermal technologies enable the development of innovative new products through the simple, safe and efficient delivery of both small and large molecule therapeutics, which provides significant clinical and commercial advantages, including valuable product lifecycle management.
Type
Public
HQ
Menlo Park, US
Size (employees)
212 (est)-14%
Corium International is headquartered in Menlo Park, US

Key People at Corium International

Christina Dickerson

Christina Dickerson

Vice President of Corporate Development

Corium International Office Locations

Corium International has offices in Menlo Park and Kentwood
Menlo Park, US (HQ)
235 Constitution Dr
Kentwood, US
4558 50th St Se

Corium International Metrics

Corium International Financial Metrics

Market capitalization (28-Apr-2017)

$131.8 m

Closing share price (28-Apr-2017)

$4.5

Cash (30-Sep-2016)

$39.8 m
Corium International's current market capitalization is $131.8 m.
FY, 2014FY, 2015FY, 2016

Cash

$36.4 m$72.2 m$39.8 m

Accounts Receivable

$4.2 m$4.5 m$4.3 m

Inventories

$1.3 m$1.4 m$2.4 m

Current Assets

$45.8 m$81.8 m$48.3 m

PP&E

$12.7 m$11.6 m$11.1 m

Total Assets

$65.7 m$100.7 m$67.2 m

Accounts Payable

$2.5 m$4 m$2.7 m

Current Liabilities

$8.5 m$9.8 m$8 m

Additional Paid-in Capital

$114.1 m$166.1 m$170.3 m

Retained Earnings

($102.3 m)($130.8 m)($167.5 m)

Total Equity

$11.8 m$35.3 m$2.9 m

Financial Leverage

5.6 x2.9 x23.5 x
FY, 2014FY, 2015FY, 2016

Accounts Receivable

($1 m)($293 k)$125 k

Inventories

($255 k)($75 k)$478 k

Accounts Payable

$700 k$1.4 m($1.2 m)

Cash From Operating Activities

($11.4 m)($20.7 m)($29.1 m)

Purchases of PP&E

($3.2 m)($973 k)($1.4 m)

Cash From Investing Activities

($3.7 m)($1.7 m)($3 m)

Long-term Borrowings

($484 k)($67 k)($72 k)

Cash From Financing Activities

$37.9 m$58.3 m($298 k)

Interest Paid

$4.7 m$5.6 m$5.9 m

Income Taxes Paid

$2 k$2 k$3 k
Y, 2016

Financial Leverage

23.5 x

Corium International Market Value History

Corium International Online Presence

Corium International Company Life

You may also be interested in